These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
439 related articles for article (PubMed ID: 33293006)
1. Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19. Khan MSI; Khan MSI; Debnath CR; Nath PN; Mahtab MA; Nabeka H; Matsuda S; Akbar SMF Arch Bronconeumol (Engl Ed); 2020 Dec; 56(12):828-830. PubMed ID: 33293006 [No Abstract] [Full Text] [Related]
2. Antiviral and Anti-Inflammatory Properties of Ivermectin and Its Potential Use in COVID-19. Portmann-Baracco A; Bryce-Alberti M; Accinelli RA Arch Bronconeumol (Engl Ed); 2020 Dec; 56(12):831. PubMed ID: 32736876 [No Abstract] [Full Text] [Related]
3. Ivermectin for preventing and treating COVID-19. Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930 [TBL] [Abstract][Full Text] [Related]
4. Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19. Aref ZF; Bazeed SEES; Hassan MH; Hassan AS; Rashad A; Hassan RG; Abdelmaksoud AA Int J Nanomedicine; 2021; 16():4063-4072. PubMed ID: 34163159 [TBL] [Abstract][Full Text] [Related]
5. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19. Formiga FR; Leblanc R; de Souza Rebouças J; Farias LP; de Oliveira RN; Pena L J Control Release; 2021 Jan; 329():758-761. PubMed ID: 33038449 [TBL] [Abstract][Full Text] [Related]
6. COVID-19 update: NIH recommends against ivermectin. Med Lett Drugs Ther; 2022 Jun; 64(1652):95-96. PubMed ID: 35657909 [No Abstract] [Full Text] [Related]
7. Safety cannot justify the use of ivermectin for the management of COVID-19. Deng J; Heybati K; Hou W; Zuo QK QJM; 2022 Mar; 115(3):194-195. PubMed ID: 35080630 [No Abstract] [Full Text] [Related]
8. The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ? Jans DA; Wagstaff KM Biochem Biophys Res Commun; 2021 Jan; 538():163-172. PubMed ID: 33341233 [TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial. Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826 [TBL] [Abstract][Full Text] [Related]
11. Potential therapeutic effects of Ivermectin in COVID-19. Barati N; Motavallihaghi S; Nikfar B; Chaichian S; Momtazi-Borojeni AA Exp Biol Med (Maywood); 2022 Aug; 247(15):1388-1396. PubMed ID: 35686662 [TBL] [Abstract][Full Text] [Related]
12. Role of ivermectin in patients hospitalized with COVID-19: a systematic review of literature. Chaudhry MW; Zubair SM; Zubairi ABS; Irfan M Adv Respir Med; 2021; 89(4):413-418. PubMed ID: 34494244 [TBL] [Abstract][Full Text] [Related]
13. Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19. Khan MSI; Khan MSI; Debnath CR; Nath PN; Mahtab MA; Nabeka H; Matsuda S; Akbar SMF Arch Bronconeumol (Engl Ed); 2020 Dec; 56(12):828-830. PubMed ID: 33994641 [No Abstract] [Full Text] [Related]
14. Effect of Ivermectin in the Treatment of Coronavirus Disease 2019: A Trial Sequential Analysis Highlights the Requirement of Additional Randomized, Controlled Trials. Padhi S; Pati A; Panda AK Clin Infect Dis; 2022 Mar; 74(6):1120-1121. PubMed ID: 34357386 [No Abstract] [Full Text] [Related]
15. A Global Early Empirical Therapy Randomized Study Design for Ivermectin in SARS-CoV-2 Infection. Bhaskar E Am J Ther; 2021 May; 28(4):e522-e523. PubMed ID: 34117145 [No Abstract] [Full Text] [Related]
16. A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2. Kinobe RT; Owens L Fundam Clin Pharmacol; 2021 Apr; 35(2):260-276. PubMed ID: 33427370 [TBL] [Abstract][Full Text] [Related]
17. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289 [TBL] [Abstract][Full Text] [Related]
18. COVID-19 in pediatric cancer patients in a resource-limited setting: National data from Peru. Montoya J; Ugaz C; Alarcon S; Maradiegue E; García J; Díaz R; Zapata A; Chávez S; Morales R; Ordoñez K; Hernandez E; Reaño R; Gutierrez C; Vargas MP; Sanchez K; Valdiviezo C; Maza I; Rojas N; Moore C; León E; Vásquez L Pediatr Blood Cancer; 2021 Feb; 68(2):e28610. PubMed ID: 32779840 [No Abstract] [Full Text] [Related]
19. Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. Lima-Morales R; Méndez-Hernández P; Flores YN; Osorno-Romero P; Sancho-Hernández CR; Cuecuecha-Rugerio E; Nava-Zamora A; Hernández-Galdamez DR; Romo-Dueñas DK; Salmerón J Int J Infect Dis; 2021 Apr; 105():598-605. PubMed ID: 33578014 [TBL] [Abstract][Full Text] [Related]
20. Reply to "Antiviral and anti-inflammatory properties of ivermectinand its potential use in COVID-19". Accinelli RA; Portmann-Baracco A; Bryce-Alberti M Arch Bronconeumol (Engl Ed); 2020 Dec; 56(12):833. PubMed ID: 33268141 [No Abstract] [Full Text] [Related] [Next] [New Search]